SG11201502430QA - Use of an ion exchange membrane to remove impurities from cell-binding agent cytotoxic agent conjugates - Google Patents

Use of an ion exchange membrane to remove impurities from cell-binding agent cytotoxic agent conjugates

Info

Publication number
SG11201502430QA
SG11201502430QA SG11201502430QA SG11201502430QA SG11201502430QA SG 11201502430Q A SG11201502430Q A SG 11201502430QA SG 11201502430Q A SG11201502430Q A SG 11201502430QA SG 11201502430Q A SG11201502430Q A SG 11201502430QA SG 11201502430Q A SG11201502430Q A SG 11201502430QA
Authority
SG
Singapore
Prior art keywords
cell
ion exchange
exchange membrane
remove impurities
binding agent
Prior art date
Application number
SG11201502430QA
Other languages
English (en)
Inventor
Xinfang Li
Wenjie Cheng
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of SG11201502430QA publication Critical patent/SG11201502430QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201502430QA 2012-10-04 2013-10-04 Use of an ion exchange membrane to remove impurities from cell-binding agent cytotoxic agent conjugates SG11201502430QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261709871P 2012-10-04 2012-10-04
PCT/US2013/063503 WO2014055893A1 (fr) 2012-10-04 2013-10-04 Utilisation d'une membrane échangeuse d'ions pour éliminer des impuretés de conjugués agent de fixation aux cellules-agent cytotoxique

Publications (1)

Publication Number Publication Date
SG11201502430QA true SG11201502430QA (en) 2015-04-29

Family

ID=50435480

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201502430QA SG11201502430QA (en) 2012-10-04 2013-10-04 Use of an ion exchange membrane to remove impurities from cell-binding agent cytotoxic agent conjugates

Country Status (13)

Country Link
US (1) US20150307596A1 (fr)
EP (1) EP2903450A4 (fr)
JP (1) JP2015535215A (fr)
CN (1) CN105208876A (fr)
AU (1) AU2013326897A1 (fr)
CA (1) CA2886996A1 (fr)
HK (1) HK1213148A1 (fr)
IL (1) IL238111A0 (fr)
IN (1) IN2015DN03203A (fr)
MX (1) MX2015004258A (fr)
RU (1) RU2015116883A (fr)
SG (1) SG11201502430QA (fr)
WO (1) WO2014055893A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1928503T1 (sl) 2005-08-24 2012-11-30 Immunogen Inc Postopek za pripravo konjugatov majtansinoid protitelo
TR201907573T4 (tr) 2009-06-03 2019-06-21 Immunogen Inc Konjugasyon yöntemleri̇
KR20220009505A (ko) 2011-03-29 2022-01-24 이뮤노젠 아이엔씨 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조
US10035817B2 (en) * 2012-10-04 2018-07-31 Immunogen, Inc. Method of purifying cell-binding agent-cytotoxic agent conjugates with a PVDF membrane
GB201616758D0 (en) * 2016-10-03 2016-11-16 Ge Healthcare Bio Sciences Ab Novel chromatography media
CN108549763B (zh) * 2018-04-09 2021-06-01 电子科技大学 一种用于离子推进器数值模拟的电荷交换碰撞mcc方法
CN118290513A (zh) * 2024-06-05 2024-07-05 东曜药业有限公司 一种去除抗体偶联药物中游离小分子的阴离子柱层析方法及抗体偶联药物
CN118290514A (zh) * 2024-06-05 2024-07-05 东曜药业有限公司 基于阴离子膜的抗体偶联药物的纯化方法及抗体偶联药物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005532258A (ja) * 2002-01-03 2005-10-27 スミスクライン・ビーチャム・コーポレイション 免疫コンジュゲートの調製方法
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
EP2468304A3 (fr) * 2005-02-11 2012-09-26 ImmunoGen, Inc. Procédé de préparation de conjugués de médicaments stables
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
SI1928503T1 (sl) * 2005-08-24 2012-11-30 Immunogen Inc Postopek za pripravo konjugatov majtansinoid protitelo
TR201907573T4 (tr) * 2009-06-03 2019-06-21 Immunogen Inc Konjugasyon yöntemleri̇
KR20220009505A (ko) * 2011-03-29 2022-01-24 이뮤노젠 아이엔씨 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조

Also Published As

Publication number Publication date
CN105208876A (zh) 2015-12-30
EP2903450A4 (fr) 2016-05-11
AU2013326897A1 (en) 2015-05-07
WO2014055893A1 (fr) 2014-04-10
IN2015DN03203A (fr) 2015-10-02
RU2015116883A (ru) 2016-11-27
MX2015004258A (es) 2015-09-25
HK1213148A1 (zh) 2016-06-30
IL238111A0 (en) 2015-05-31
JP2015535215A (ja) 2015-12-10
EP2903450A1 (fr) 2015-08-12
CA2886996A1 (fr) 2014-04-10
US20150307596A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
IL277652B (en) Stable aqueous formulations of adlimumab
IL238111A0 (en) Using an Ion Permeable Membrane to Remove Cytotoxic Factor and Cell Binding Factor Adherent Contaminants
ZA201605918B (en) Preparation of cell-binding agent cytotoxic agent conjugates
IL268378A (en) Using a polyvinyl difluoride membrane to purify conjugates of a cytotoxic factor and a cell-binding factor
HK1212701A1 (zh) 恩雜魯胺製劑
HK1213174A1 (zh) 穩定的含水依那西普製劑
SG10201609982PA (en) Pharmaceutical formulations of tnf-alpha anitbodies
ZA201500212B (en) Progesterone formulations
PT3336097T (pt) Preparação da forma não cristalina de ácido obeticólico
SG11201405605VA (en) SUPPRESSOR CELL FUNCTION INHIBITION FOLLOWING <i>LISTERIA</i> VACCINE TREATMENT
PT2908835T (pt) Formulações estáveis
EP2867199A4 (fr) Compositions stables de fésotérodine
EP2754451A4 (fr) Utilisation d'ache comme nucléase
IL233879A0 (en) Dry powdered dnase i preparations